The cost of treating allergic rhinitis
- PMID: 11918864
- DOI: 10.1007/s11882-002-0023-0
The cost of treating allergic rhinitis
Abstract
Allergic rhinitis is a high-cost, high-prevalence disease. In the year 2000, over $6 billion was spent on prescription medications to treat this illness. Although it is not associated with severe morbidity and mortality, allergic rhinitis has a major effect on the quality of life of the more than 50 million Americans with this illness. Intranasal corticosteroids (INCS) and nonsedating antihistamines (NSAH) are the most common prescription medications for this disease. INCS are recognized as the most effective treatment regimen for chronic symptoms. NSAH are perceived as important in the treatment of patients with mild disease, or as add-on therapy to INCS. When the literature is reviewed, the INCS produce the greatest decrease in total nasal symptom scores, the largest effect size, when compared with NSAH. Both classes of medications produce similar effects on concurrent allergic conjunctivitis. Further recent studies indicate that the INCS are also superior when used on an as-needed basis, and that there is little clinical benefit from the addition of loratadine to intranasal fluticasone. INCS have lower average wholesale prices as a class than the NSAH. Since the INCS are the dominant medication in efficacy studies and cost less, cost-effectiveness studies always favor intranasal corticosteroids.
Similar articles
-
Cost-effective pharmacotherapy for allergic rhinitis.Otolaryngol Clin North Am. 1998 Feb;31(1):91-110. doi: 10.1016/s0030-6665(05)70032-3. Otolaryngol Clin North Am. 1998. PMID: 9530680 Review.
-
Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines.Am J Manag Care. 1998 Jan;4(1):89-96. Am J Manag Care. 1998. PMID: 10179909
-
Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.Pharmacoeconomics. 2004;22(14):929-42. doi: 10.2165/00019053-200422140-00003. Pharmacoeconomics. 2004. PMID: 15362929
-
Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials.Am J Respir Med. 2003;2(1):55-65. doi: 10.1007/BF03256639. Am J Respir Med. 2003. PMID: 14720022 Review.
-
A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis.Am J Manag Care. 2001 May;7(4 Suppl):S103-12. Am J Manag Care. 2001. PMID: 11392821
Cited by
-
The effect of face mask usage on the allergic rhinitis symptoms in patients with pollen allergy during the covid-19 pandemic.Am J Otolaryngol. 2022 Jan-Feb;43(1):103206. doi: 10.1016/j.amjoto.2021.103206. Epub 2021 Sep 10. Am J Otolaryngol. 2022. PMID: 34534761 Free PMC article.
-
Clinical associations between allergies and rapid eye movement sleep disturbances.Int Forum Allergy Rhinol. 2018 Jul;8(7):817-824. doi: 10.1002/alr.22099. Epub 2018 Feb 20. Int Forum Allergy Rhinol. 2018. PMID: 29461689 Free PMC article.
-
Economic Evaluation of Quality-of-Life Improvement with Second-Generation Antihistamines and Montelukast in Patients with Allergic Rhinitis.Am Health Drug Benefits. 2009 Nov;2(7):309-16. Am Health Drug Benefits. 2009. PMID: 25126304 Free PMC article.
-
Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms.Am Health Drug Benefits. 2008 Oct;1(8):26-34. Am Health Drug Benefits. 2008. PMID: 25126257 Free PMC article.
-
Underdiagnosed and Undertreated Allergic Rhinitis in Urban School-Aged Children with Asthma.Pediatr Allergy Immunol Pulmonol. 2014 Jun 1;27(2):75-81. doi: 10.1089/ped.2014.0344. Pediatr Allergy Immunol Pulmonol. 2014. PMID: 24963455 Free PMC article.